A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.
There is a critical need to non-invasively and remotely manipulate cells at a distance, particularly for translational applications in animals and humans, researchers said.
The team developed an innovative approach to use mechanogenetics—a field of science that focuses on how physical forces and changes in the mechanical properties of cells and tissues influence gene expression—for the remote control of gene and cell activations. Researchers used ultrasound to mechanically perturb T cells, and then converted the mechanical signals into genetic control of cells.
In this study, researchers show how their remote-controlled mechanogenetics system can be used to engineer chimeric antigen receptor (CAR)-expressing T cells that can target and kill cancer cells. The engineered CAR-T cells have mechano-sensors and genetic transducing modules that can be remotely activated by ultrasound via microbubble amplification.
“CAR-T cell therapy is becoming a paradigm-shifting therapeutic approach for cancer treatment,” said bioengineering professor Peter Yingxiao Wang at the University of California San Diego. “However, major challenges remain before CAR-based immunotherapy can become widely adopted. For instance, the non-specific targeting of CAR-T cells against nonmalignant tissues can be life-threatening. This work could ultimately lead to an unprecedented precision and efficiency in CAR-T cell immunotherapy against solid tumors, while minimizing off-tumor toxicities.”
The team brings together the laboratories of professors Wang and Shu Chien, both bioengineering professors at the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego, in collaboration with professors Kirk Shung of the University of Southern California and Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. Researchers present their findings in the Jan. 15 issue of the Proceedings of the National Academy of Sciences, with UC San Diego Ph.D. candidate Yijia Pan as the first author.
Researchers found that microbubbles conjugated to streptavidin can be coupled to the surface of a cell, where mechanosensitive Piezo1 ion channels are expressed. Upon exposure to ultrasound waves, microbubbles vibrate and mechanically stimulate Piezo1 ion channels to let calcium ions inside the cell. This triggers downstream pathways, including calcineurin activation, NFAT dephoshorylation and translocation into the nucleus. The nucleus-translocated NFAT can bind to upstream response elements of genetic transducing modules to initiate gene expression of chimeric antigen receptor (CAR) for the recognition and killing of target cancer cells.
The Latest on: CAR-T cell therapy
- CAR T-Cell Therapy a 'Really Exciting' Development in Treatment of Lymphomason May 21, 2020 at 6:29 am
The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.
- Real-World CAR T-Cell Therapy Continues Its Promiseon May 20, 2020 at 3:45 pm
You might imagine when you're outside of the confines of eligibility criteria, you're going to have sicker patients with more morbidities, and that's exactly what we found." CAR T-cell therapy has had ...
- FDA clears IND application for CAR T-cell therapy targeting gastric, pancreatic cancerson May 20, 2020 at 7:15 am
The FDA cleared an investigational new drug application for CT041, a chimeric antigen receptor T-cell therapy for the treatment of adenocarcinoma of the stomach, gastroesophageal junction or pancreas.
- Boosting the power of immunotherapy for more effective cancer treatmenton May 19, 2020 at 7:21 am
Adoptive T cell therapies, including chimeric antigen receptor (CAR) T cell therapy, which use genetically engineered killer immune T cells, are emerging forms of immunotherapy that redirect the ...
- University of Chicago Medicine receives $10M gift for research in cancer treatmenton May 18, 2020 at 3:05 pm
University of Chicago Medicine announced Monday it received a $10 million gift from a Chicago area investor to fund research for cellular therapy used to fight certain types of cancer.
- WuXi Advanced Therapies Launches New Closed Process CAR-T Cell Therapy Platformon May 18, 2020 at 6:00 am
WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services ...
- More cancer patients could benefit from CAR T-cell therapy, Moffitt study suggestson May 14, 2020 at 3:58 pm
Chimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments.
- Study suggests more could benefit from CAR T-cell therapyon May 14, 2020 at 10:59 am
Chimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments. The therapy uses a ...
- Moffitt Cancer Center study suggests more could benefit from CAR T-cell therapyon May 14, 2020 at 9:22 am
Moffitt Cancer Center organized a consortium of 16 cancer treatment facilities across the US that offer Yescarta as a standard-of-care therapy for patients with relapsed/refractory large B cell ...
- Updated Results from Phase 1b/2 Study of BCMA CAR-T Therapy JNJ-4528 Shows Early, Deep and Durable Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple ...on May 13, 2020 at 3:42 pm
Legend Biotech Corporation (“Legend”) announced today updated results from the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”) s ...
via Google News and Bing News